Archive
-
WFH 2016 World Congress program focuses on the future of treatment
Over the past decade, the global bleeding disorders community has witnessed great strides in the research of new treatments and methods of care. During the...
-
Collaboration between patients and healthcare professionals demonstrates the unique strength of the WFH
When does a patient’s personal experience intersect with the successful delivery of treatment? Is it at the start of receiving care? Is it after treatment...
-
Generating evidence to support clinical management and ensure access
We have entered an era of unprecedented growth in treatment options for hemophilia. A number of new treatments have, or will soon, enter the market,...
-
EMA investigating rare adverse events associated with hepatitis C treatment
The European Medicines Agency (EMA) has started a review of medicines known as direct-acting antivirals used for treating chronic hepatitis C infection. There have been...
-
Access barrier to groundbreaking hepatitis C treatments
New medications unveiled in the last two years have revolutionized the treatment of hepatitis C (HCV) drastically improving patients’ chances of a cure. The challenge...
-
World Hemophilia Day 2016
In 2016 the World Federation of Hemophilia (WFH) is working with the global bleeding disorders community to focus on the theme of Treatment for All...
-
WFH Collaboration with EHC and EAHAD in Estonia
For many national hemophilia organizations, the path to improving hemophilia healthcare in their countries comes from the many contributions from both global and regional partners....
-
The power of information: Afghanistan’s first contribution to the WFH Annual Global Survey
Every year, national aggregate data is collected from World Federation of Hemophilia (WFH) national member organizations (NMOs) and published in the Report on the WFH...
-
Providing guidance on product selection
There are several new treatment products for bleeding disorders available today and over the next couple of years, even more will likely become available to...
-
The Forum for Latin America
Over the last few decades, many of the World Federation of Hemophilia (WFH) national member organizations (NMOs) in Latin America have expanded their networks, become...
-
World Federation of Hemophilia product selection statement
The selection of safe, effective medicinal products is the responsibility of national regulatory and health agencies. In the case of clotting factor concentrates, whether plasma-derived...
-
Continuing support to Morocco under the GAP Second Decade Program
During a visit to Morocco in October 2015, World Federation of Hemophilia (WFH) president Alain Weill, and a representative from the Moroccan Ministry of Health...
